Senior Research Fellow
PharmDr. Silvester Poništ, PhD.
T:
02/32295730
ORCID:
Our pharmacological research is focusing on new therapeutic combinations of the classical immunosuppressive treatment (represented by methotrexate-MTX) with immunomodulators and compounds affecting redox homeostasis in experimental arthritis - model of rheumatoid arthritis (RA). We study particularly natural substances to improve standard therapy of RA by MTX and to minimize the administration of biological therapy. Moreover, elucidation of the mechanism of action of these substances in treatment of chronic inflammatory diseases, could “bring them” into the evidence based medicine. For this purpose we are aimed to study the connection between systemic and local oxidative stress, inflammatory processes and cachexia.